Aarti Pharmalabs Limited

Aarti Pharmalabs Limited

1,015.00
INR
+28.75
(+2.92%)
28.29EPS
33.64P/E
86.35BMarket Cap
Feb 10Next Earn

Total Valuation

INR

As of September 30, 2026, Aarti Pharmalabs Limited carries a market capitalization of 86.35B, placing it among publicly traded companies globally. Its enterprise value stands at 95.09B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap86.35B
Enterprise Value95.09B

Important Dates

Aarti Pharmalabs Limited's next confirmed earnings release is scheduled for February 10, 2027.

Earnings Date2/10/2027

Share Statistics

As of September 30, 2026, Aarti Pharmalabs Limited has 90.68M shares outstanding.

Shares Outstanding90.68M

Valuation Ratios

As of September 30, 2026, Aarti Pharmalabs Limited trades at a trailing price-to-earnings ratio of 33.64. The price-to-sales ratio is 4.00, and the price-to-book ratio stands at 3.83.

PE Ratio33.64
PS Ratio4.00
PB Ratio3.83
P/TBV Ratio4.08

Enterprise Valuation

As of September 30, 2026, Aarti Pharmalabs Limited trades at an EV/EBITDA multiple of 19.21 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.40 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 25.19 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 95.09B versus a market cap of 86.35B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales4.40
EV / EBITDA19.21
EV / EBIT25.19

Financial Position

As of September 30, 2026, Aarti Pharmalabs Limited maintains a current ratio of 1.40, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 39.79, indicating elevated leverage, while an interest coverage ratio of 8.64 demonstrates adequate ability to service its debt obligations.

Current Ratio1.40
Quick Ratio0.02
Debt / Equity39.79
Debt / EBITDA1.81
Interest Coverage8.64

Financial Efficiency

INR

Over the twelve months ended September 30, 2026, Aarti Pharmalabs Limited posted a return on equity (ROE) of 11.94, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 9.71 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.24, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 10.24, useful for judging operating efficiency across full business cycles. The company generates approximately 5.52M in revenue per employee across its workforce of 3,914.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.40 indicates how many times Aarti Pharmalabs Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)11.94
Return on Assets (ROA)7.24
Return on Invested Capital (ROIC)9.71
Return on Capital Employed (ROCE)10.24
Revenue Per Employee5.52M
Employee Count3,914.75
Inventory Turnover1.40

Taxes

INR

Over the twelve months ended September 30, 2026, Aarti Pharmalabs Limited recorded 839.03M in income tax expense. That works out to an effective tax rate of 24.63, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 3.41B, leaving 2.57B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax839.03M
Effective Tax Rate24.63

Stock Price Statistics

INR

As of the close on November 17, 2026, Aarti Pharmalabs Limited's stock has gained approximately 39.20% over the past 52 weeks. The 50-day moving average sits at 895.61, while the 200-day moving average is 759.31.

52-Week Price Change39.20%
50-Day Moving Average895.61
200-Day Moving Average759.31

Income Statement

INR

Over the twelve months ended September 30, 2026, Aarti Pharmalabs Limited generated 21.61B in revenue and converted that into 2.57B in net income, yielding earnings per share of 28.29. EBITDA reached 4.95B, while operating income came in at 3.82B.

Revenue21.61B
Gross Profit11.70B
Operating Income3.82B
Pretax Income3.41B
Net Income2.57B
EBITDA4.95B
EBIT3.78B
Earnings Per Share (EPS)28.29

Balance Sheet

INR

As of September 30, 2026, Aarti Pharmalabs Limited holds 235.09M in cash and equivalents against 8.97B in total debt, resulting in a net debt position of 8.32B. Total book value stands at 22.55B, with working capital of 4.77B providing operational flexibility.

Cash & Cash Equivalents235.09M
Total Debt8.97B
Net Debt8.32B
Equity (Book Value)22.55B
Book Value Per Share248.65
Working Capital4.77B

Margins

Over the twelve months ended September 30, 2026, Aarti Pharmalabs Limited posted a gross margin of 54.14, reflecting its pricing power and cost economics. The operating margin of 17.69 and net profit margin of 11.88 provide insight into operational efficiency.

Gross Margin54.14
Operating Margin17.69
Pretax Margin15.76
Profit Margin11.88
EBITDA Margin22.90